216 related articles for article (PubMed ID: 26162631)
1. Detection of expanded-spectrum β-lactamases in Gram-negative bacteria in the 21st century.
Al-Bayssari C; Dabboussi F; Hamze M; Rolain JM
Expert Rev Anti Infect Ther; 2015; 13(9):1139-58. PubMed ID: 26162631
[TBL] [Abstract][Full Text] [Related]
2. Dissemination of IncF plasmids carrying beta-lactamase genes in Gram-negative bacteria from Nigerian hospitals.
Ogbolu DO; Daini OA; Ogunledun A; Terry Alli OA; Webber MA
J Infect Dev Ctries; 2013 May; 7(5):382-90. PubMed ID: 23669427
[TBL] [Abstract][Full Text] [Related]
3. [Clinically important beta-lactamases of gram-negative bacteria: extended-spectrum beta-lactamases (ESBL)].
Hrabák J
Epidemiol Mikrobiol Imunol; 2007 Aug; 56(3):103-11. PubMed ID: 17900058
[TBL] [Abstract][Full Text] [Related]
4. Molecular epidemiology of extended-spectrum β-lactamase-, AmpC β-lactamase- and carbapenemase-producing Escherichia coli and Klebsiella pneumoniae isolated from Canadian hospitals over a 5 year period: CANWARD 2007-11.
Denisuik AJ; Lagacé-Wiens PR; Pitout JD; Mulvey MR; Simner PJ; Tailor F; Karlowsky JA; Hoban DJ; Adam HJ; Zhanel GG;
J Antimicrob Chemother; 2013 May; 68 Suppl 1():i57-65. PubMed ID: 23587779
[TBL] [Abstract][Full Text] [Related]
5. Detection of gram-negative β-lactamase producing pathogens in the clinical lab.
Thomson KS
Curr Pharm Des; 2013; 19(2):250-6. PubMed ID: 22894616
[TBL] [Abstract][Full Text] [Related]
6. Characteristics, epidemiology and clinical importance of emerging strains of Gram-negative bacilli producing extended-spectrum beta-lactamases.
Shah AA; Hasan F; Ahmed S; Hameed A
Res Microbiol; 2004; 155(6):409-21. PubMed ID: 15249058
[TBL] [Abstract][Full Text] [Related]
7. [Identification and classification of beta-lactamases in clinical isolates of bacteria].
Inoue M; Nakano R; Hosaka Y; Okitsu N; Kaneko K; Komatsu Y; Kitasato H; Okamoto R
Jpn J Antibiot; 2002 Sep; 55 Suppl A():29-41. PubMed ID: 12599527
[TBL] [Abstract][Full Text] [Related]
8. Phenotypic detection and polymerase chain reaction screening of extended-spectrum β-lactamases produced by Pseudomonas aeruginosa isolates.
Lin SP; Liu MF; Lin CF; Shi ZY
J Microbiol Immunol Infect; 2012 Jun; 45(3):200-7. PubMed ID: 22209695
[TBL] [Abstract][Full Text] [Related]
9. Prevalence of multidrug-resistant gram-negative bacilli producing extended-spectrum β-lactamases (ESBLs) and ESBL genes in solid organ transplant recipients.
Men TY; Wang JN; Li H; Gu Y; Xing TH; Peng ZH; Zhong L
Transpl Infect Dis; 2013 Feb; 15(1):14-21. PubMed ID: 23013385
[TBL] [Abstract][Full Text] [Related]
10. [Broad-spectrum beta-lactamases. Clinical significance and detection methods].
Sidorenko SV
Antibiot Khimioter; 2001; 46(12):27-34. PubMed ID: 12108090
[No Abstract] [Full Text] [Related]
11. Tracing of false negative results in phenotypic methods for identification of carbapenemase by Real-time PCR.
Azimi L; Talebi M; Owlia P; Pourshafie MR; Najafi M; Lari ER; Lari AR
Gene; 2016 Jan; 576(1 Pt 1):166-70. PubMed ID: 26456106
[TBL] [Abstract][Full Text] [Related]
12. [Detection of resistance phenotypes in gram-negative bacteria].
Navarro F; Calvo J; Cantón R; Fernández-Cuenca F; Mirelis B
Enferm Infecc Microbiol Clin; 2011; 29(7):524-34. PubMed ID: 21696863
[TBL] [Abstract][Full Text] [Related]
13. [Broad-spectrum beta-lactamases in Gram-negative bacteria].
Sundsfjord A; Simonsen GS; Haldorsen B; Lundblad EW; Samuelsen O
Tidsskr Nor Laegeforen; 2008 Dec; 128(23):2741-5. PubMed ID: 19079424
[TBL] [Abstract][Full Text] [Related]
14. Resistance to cephalosporins and carbapenems in Gram-negative bacterial pathogens.
Pfeifer Y; Cullik A; Witte W
Int J Med Microbiol; 2010 Aug; 300(6):371-9. PubMed ID: 20537585
[TBL] [Abstract][Full Text] [Related]
15. Extended-spectrum beta-lactamases in the 21st century: characterization, epidemiology, and detection of this important resistance threat.
Bradford PA
Clin Microbiol Rev; 2001 Oct; 14(4):933-51, table of contents. PubMed ID: 11585791
[TBL] [Abstract][Full Text] [Related]
16. [Clinically important beta-lactamases of gram-negative bacteria: AmpC].
Hrabák J
Epidemiol Mikrobiol Imunol; 2007 Nov; 56(4):155-65. PubMed ID: 18064797
[TBL] [Abstract][Full Text] [Related]
17. Risks of extended-spectrum beta-lactamases.
BMJ Group
Drug Ther Bull; 2008 Mar; 46(3):21-4. PubMed ID: 18337463
[TBL] [Abstract][Full Text] [Related]
18. Probe ligation and real-time detection of KPC, OXA-48, VIM, IMP, and NDM carbapenemase genes.
Cuzon G; Naas T; Bogaerts P; Glupczynski Y; Nordmann P
Diagn Microbiol Infect Dis; 2013 Aug; 76(4):502-5. PubMed ID: 23791387
[TBL] [Abstract][Full Text] [Related]
19. In vitro susceptibility of characterized β-lactamase-producing Gram-negative bacteria isolated in Japan to ceftazidime-, ceftaroline-, and aztreonam-avibactam combinations.
Yoshizumi A; Ishii Y; Aoki K; Testa R; Nichols WW; Tateda K
J Infect Chemother; 2015 Feb; 21(2):148-51. PubMed ID: 25444674
[TBL] [Abstract][Full Text] [Related]
20. What are extended-spectrum beta-lactamases?
Sutton SS
JAAPA; 2014 Mar; 27(3):14-7. PubMed ID: 24566339
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
